Revolution Medicines dips as $142 follow-on and $500M convertibles add near-term supply
Revolution Medicines shares are sliding as investors digest the company’s newly priced $142-per-share follow-on equity offering that added ~12.15 million shares, raising expected net proceeds of about $1.7 billion. The stock is also facing near-term supply/dilution and hedging pressure from the concurrent $500 million convertible notes priced with an initial conversion price near $198.80.
1) What’s moving the stock today
Revolution Medicines (RVMD) is down about 3% as traders price in dilution and incremental share supply from the company’s recent financing. The company priced a follow-on offering at $142 per share, including full exercise of the underwriters’ option, bringing the deal to 12,147,887 shares and expected net proceeds of roughly $1.7 billion.
2) The financing overhang investors are trading
Beyond the common-stock issuance, Revolution also priced $500 million of 0.50% convertible senior notes due 2033. The notes’ initial conversion price is about $198.80 per share (roughly a 40% premium to the $142 stock-offering price), a structure that can create near-term technical pressure as investors anticipate hedging flows and additional effective supply.
3) Why the pullback is happening now (timing/technicals)
RVMD recently surged after strong clinical headlines, pushing the stock into the mid-$140s. With the equity deal priced at $142, the market is now gravitating toward the offering level as new shares are absorbed and investors reassess near-term positioning after the sharp run-up.
4) What to watch next
Key signposts are post-deal trading volume and whether RVMD can hold above the $142 offering price once the financing is fully digested. Investors will also focus on how quickly the company deploys the proceeds into late-stage development and commercialization preparation tied to daraxonrasib.